share_log

Hepion Pharmaceutical's Lead Drug Shows Antifibrotic Effects In Animal Studies

Benzinga Real-time News ·  Mar 23, 2021 10:10

Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has announced positive results from an in vivo study of CRV431.

  • In this study, the mouse model was treated for eight weeks with oral dosing of CRV431, or two comparator drugs, obeticholic acid, and elafibranor.
  • Fibrosis was reduced by 47% with CRV431, 35% with obeticholic acid, and 37% with elafibranor, relative to vehicle controls.
  • The company says that the results highlight a relatively short course of CRV431 treatment that can exert beneficial effects at an advanced stage of liver disease.
  • Price Action: HEPA shares trading 0.89% higher at $2.12 in market hours on the last check Tuesday.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment